Introducing Cellanyx
Cellanyx is a growth stage emerging biotech advancing proprietary phenotypic (appearance and dynamics) biomarker tests based on Machine Vision and AI-driven analysis of live single tumor cells to improve risk-stratification and shared clinical decision-making for solid tumors. LDT evaluated in nearly 500 patient samples across prostate, breast, kidney, bladder and lung cancers. Learn more
Patients
Increased confidence in shared decision-making of treatment plans for multiple solid tumors including prostate, breast, kidney, bladder and lung cancers.
Clinicians
Augmenting Pathology with a Novel LDT (Laboratory Developed Test) based on live single tumor cell phenotypic analysis to improve risk stratification of tumor aggressiveness
Third-Party Payors
Reduction in unnecessary treatment costs associated with surgeries or radiation for low-to-intermediate grade tumors
Investors
First in class, clinically-proven, patented, scalable and portable machine-vision and AI-driven phenotypic cancer risk stratification test to improve actionability and outcomes
Cellanyx News
LATEST PRESS
January 19, 2021:
Nilesh Patel Joins Cellanyx Board of Directors
February 21, 2019:
Cellanyx Publication Chosen As Cover of the February Edition of the Journal Urology.
December 13, 2018:
Cellanyx CEO Interviewed for 360Dx Article Covering Cellanyx’s Latest Publication.
PUBLICATIONS & PRESENTATIONS
April 28, 2021:
Cellanyx Publishes “Cellanyx Publishes Paper on MVL/AI driven Test to Predict
Prostate Cancer Tumor Aggressiveness in Reviews in Urology journal.
December 19, 2018:
Cellanyx Publishes Results of Clinical Proof-of-Concept Study in the Urology.
October 8, 2018:
Cellanyx Publishes Results of Clinical Validation Study in Nature Biomedical Engineering.